Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelofibrosis: early-phase trial registry
29 of 62 indexed Myelofibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #228 of 28,707 conditions by registered trial count.
62 US clinical trials · 29 currently recruiting · #228 of 28,707 conditions by registered trial count
Myelofibrosis: 62 US clinical trials tracked, 29 recruiting.
Myelofibrosis is the subject of 62 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 4 of these trials.
Enrollment posture brief
Registry condition myelofibrosis
OPEN 29 | RECR 47% | LATE 7 | EARLY 47 | RANK #228 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Female (47% recruiting · 47 trials)
Myelofibrosis lists 29 open slots (47% of 62 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelofibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelofibrosis is recruiting above its size-band peers.
29 of 62 indexed trials (46.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myelofibrosis trials is spread across many organizations.
Incyte Corporation accounts for 4 of 62 trials (6.5%). 49 distinct sponsors appear on at least one study for this condition label.
-
Most Myelofibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 62 trials that report a genuine target (sentinel values excluded). 39 of those (62.9%) plan for fewer than 100 participants.
-
Myelofibrosis research is mostly interventional.
58 interventional and 4 observational studies make up this index (93.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
62 total, page 2 of 2
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
NCT02493530
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
TargeGen
NCT00631462
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Incyte Corporation
NCT01340651
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
NCT00606437
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent
NCT01290302
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Dana-Farber Cancer Institute
NCT00136409
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Gemin X
NCT00360035
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
Weill Medical College of Cornell University
NCT00572065
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
University of Arizona
NCT00997386
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 17 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelofibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelofibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelofibrosis page
62 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Myelofibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Incyte Corporation sponsors the most Myelofibrosis trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelofibrosis condition card totals 62 registered trials; most-linked intervention Ruxolitinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.